By Iain Gilbert
Date: Tuesday 07 Oct 2025
(Sharecast News) - Cell and gene therapy outfit Oxford Biomedica said on Tuesday that it had agreed to acquire a viral vector manufacturing site in Rockville, Maryland, from ABL for $60m in cash, expanding its US footprint and strengthening its contract development and manufacturing offering.
| Holding(s) in Company | 03-Nov-2025 | 16:55 | RNS |
| Total Voting Rights | 03-Nov-2025 | 07:00 | RNS |
| Director/PDMR Shareholding | 20-Oct-2025 | 17:54 | RNS |
| Director/PDMR Shareholding | 20-Oct-2025 | 17:13 | RNS |
| Board Change | 20-Oct-2025 | 10:17 | RNS |
| Need to know: Opec cuts forecast ... Tesco cuts ... | 16-Aug-2008 | Times |
| Need to know | 10-May-2008 | Times |
| DSG International may be losing its spark | 12-Feb-2008 | Telegraph |
| Oxford BioMedica clinches $690m licensing deal f... | 29-Mar-2007 | The Independent |
| Oxford Biomedica seals €518m deal with Sanofi ov... | 29-Mar-2007 | Times |
No recent information was found.
| Currency | UK Pounds |
| Share Price | 682.00p |
| Change Today | 28.00p |
| % Change | 4.28 % |
| 52 Week High | 682.00p |
| 52 Week Low | 232.50p |
| Volume | 401,503 |
| Shares Issued | 120.50m |
| Market Cap | £821.79m |
| RiskGrade | 125 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| Strong Buy | 4 |
| Buy | 2 |
| Neutral | 4 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 10 |

| No dividends found |
| Time | Volume / Share Price |
| 15:18 | 114 @ 671.00p |
| 16:47 | 3,768 @ 659.68p |
| 16:35 | 92,626 @ 682.00p |
| 16:35 | 523 @ 682.00p |
| 16:35 | 159 @ 682.00p |
| Chair | Roch Doliveux |
| CEO | Frank Mathias |
| CFO | Lucinda (Lucy) Crabtree |
You are here: research